FINWIRES · TerminalLIVE
FINWIRES

Nuvalent Acquisition Fairly Valued, Competing Bid Seen as Unlikely, Wedbush Says

By

Nuvalent (NUVL) is fairly valued following GSK's (GSK) agreed acquisition of the company, with limited likelihood of a competing bid emerging, Wedbush Securities said in a Tuesday note.

The brokerage said most logical strategic acquirers, including Pfizer (PFE), Roche and Bristol Myers Squibb (BMY), already have meaningful exposure to ALK- and ROS1-positive non-small cell lung cancer markets, making it difficult to justify a higher offer while achieving attractive returns.

Wedbush said the deal validates the value of differentiated precision oncology assets with advantages in efficacy, tolerability, resistance mutation coverage and CNS penetration.

The investment firm downgraded Nuvalent to neutral from outperform and lowered its price target to $124 from $125, matching the agreed tender offer price from GSK.

Shares of Nuvalent rose more than 39% in Tuesday afternoon trading.

Price: $123.12, Change: $+34.63, Percent Change: +39.13%

Related Articles

Wire

Mission Produce Fiscal Q2 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Mission Produce (AVO) reported fiscal Q2 non-GAAP net income late Monday of $0.01 per diluted share, down from $0.12 a year earlier.Three analysts polled by FactSet expected $0.05.Revenue in the three months ended April 30 fell to $290.9 million from $380.3 million a year earlier.Three analysts expected $256.3 million.The board approved a stock repurchase program of up to $100 million over the next 36 months.The company's shares fell 5.9% in after-hours trading.

$AVO
Wire

Mama's Creations Fiscal Q1 Earnings, Revenue Rise

Mama's Creations (MAMA) reported fiscal Q1 earnings late Monday of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue in the three months ended April 30 rose to $52.8 million from $35.3 million a year earlier.Analysts expected $51.6 million.The company's shares fell 2.6% in after-hours trading.

$MAMA
Wire

Tango Therapeutics Launches $500 Million Stock Offering

Tango Therapeutics (TNGX) said Monday it is launching $500 million underwritten public offering of common stock.All shares are offered by the company, according to a statement.Tango said it will grant underwriters a 30-day option to purchase up to an additional $75 million of shares.

$TNGX